Table 1.

Pathological features and bone metastasis of RCC cases in this study

Case	Sex	Age	Pathologic Stage	Nodal and Metastatic Stage	Fuhrman Grade	Additional pathologic features	Bone micro- metastasisa	Histological verification of bone metastasisb	Soft tissue metastasisc	Patient outcome at 6 months
1	F	64	T3a	NxMx	III		23/31	8/14	17/31	Metastastic  disease (lung,  renal,  pancreatic)
2	M	75	T2a	NxMx	III/IV	Rhabdoid, papillary	0/4	ns	1/4	Metastatic  disease (lung)
3	M	62	T3a	NxMx	III		0/2	ns	0/2	No recurrence
4	M	68	T3a	NxMx	Chromophobe	Papillary	3/4	ns	0/4	Multiple bone  metastases
5	M	91	T3a	NxM1	III		0/7	ns	0/7	Not known
6	F	59	T3a	NxM1d	IV	Rhabdoid	0/10	0/3	0/10	Not known
7	M	42	T3a	NxMx	III		1/7	0/2	0/7	No recurrence

ns not studied

^aBone micrometastasis shows the number of mice that had bone metastasis/number of mice studied, detected by human-specific qRT-PCR

^bHistological verification of bone metastasis shows the number of mice with histologically confirmed metastasis/mice studied, detected by H&E and human-specific immunohistochemistry (human-specific Ku70 and/or CAIX-staining). In case 1, bones from 18 different TSG-bearing mice were studied and 14 of those were from mice that had bone micrometastases detected by qRT-PCR. Eight metastases of these were confirmed histologically

^cSoft tissue metastasis shows the number of mice that had soft tissue metastasis (liver or lung)/number of mice studied at sacrifice

^dThis patient underwent surgical removal of brain and bone metastases, followed by two cycles of Sunitinib, prior to nephrectomy and implantation of tissue into mice